Trump Sets 0-100-200% Tariff Escalation Schedule on Imported Generic Drugs

Washington last tried a tariff shock of this magnitude with the 1930 Smoot-Hawley Act, which raised average duties to 40 % and inadvertently shrank global trade by a third within two years; Trump’s 200 % levy targets a single, price-sensitive sector that covers 90 % of U.S. prescriptions. The move rides two longer arcs: post-COVID worries about medical supply security and a revival of industrial policy through punitive trade tools first visible in the 2018 steel tariffs. Whether it changes the system depends on cost mathematics—generic margins are in the low single digits while U.S. production costs are multiples higher—so the policy may function more as bargaining leverage than as enforceable law, mirroring Trump’s unimplemented 2025 branded-drug tariff threat. On a century scale, its significance lies less in immediate price spikes and more in testing how far a major economy will weaponize health-care interdependence; if enacted, it could accelerate the long-term fragmentation of pharmaceutical supply chains much as Cold-War export controls split semiconductor production in the 1980s, but if it fizzles, it will join a long list of headline-grabbing yet transitory tariff threats.